No Data
Peering Into Ocugen's Recent Short Interest
Earnings Call: Ocugen Reports Progress and Financials in Q2 2024
Ocugen (OCGN) Receives a Buy From Noble Financial
Buy Rating on Ocugen: Strong Financials and Promising Clinical Progress
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
Express News | Ocugen's Cash, Cash Equivalents, And Restricted Cash Totaled $16M As Of June 30, 2024, Subsequent To June 30, 2024, The Company Closed A Public Offering With Net Proceeds Of $32.6 Million—Extending Its Expected Cash Runway Into The Third Quarter Of 2025